Logo image of IRTC

IRHYTHM TECHNOLOGIES INC (IRTC) Stock Fundamental Analysis

NASDAQ:IRTC - Nasdaq - US4500561067 - Common Stock - Currency: USD

145.53  +0.58 (+0.4%)

After market: 145.53 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IRTC. IRTC was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of IRTC is average, but there are quite some concerns on its profitability. IRTC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IRTC has reported negative net income.
In the past year IRTC had a positive cash flow from operations.
IRTC had negative earnings in each of the past 5 years.
In the past 5 years IRTC reported 4 times negative operating cash flow.
IRTC Yearly Net Income VS EBIT VS OCF VS FCFIRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

IRTC has a Return On Assets of -10.62%. This is in the better half of the industry: IRTC outperforms 60.96% of its industry peers.
IRTC has a worse Return On Equity (-113.45%) than 65.24% of its industry peers.
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROIC N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
IRTC Yearly ROA, ROE, ROICIRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

With a decent Gross Margin value of 69.39%, IRTC is doing good in the industry, outperforming 79.14% of the companies in the same industry.
In the last couple of years the Gross Margin of IRTC has declined.
The Profit Margin and Operating Margin are not available for IRTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
IRTC Yearly Profit, Operating, Gross MarginsIRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

5

2. Health

2.1 Basic Checks

IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRTC has been increased compared to 1 year ago.
Compared to 5 years ago, IRTC has more shares outstanding
Compared to 1 year ago, IRTC has a worse debt to assets ratio.
IRTC Yearly Shares OutstandingIRTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRTC Yearly Total Debt VS Total AssetsIRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IRTC has an Altman-Z score of 3.24. This indicates that IRTC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IRTC (3.24) is better than 68.98% of its industry peers.
IRTC has a Debt/Equity ratio of 7.47. This is a high value indicating a heavy dependency on external financing.
IRTC has a Debt to Equity ratio of 7.47. This is amonst the worse of the industry: IRTC underperforms 91.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Altman-Z 3.24
ROIC/WACCN/A
WACC8.51%
IRTC Yearly LT Debt VS Equity VS FCFIRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

IRTC has a Current Ratio of 5.71. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC's Current ratio of 5.71 is amongst the best of the industry. IRTC outperforms 80.75% of its industry peers.
A Quick Ratio of 5.58 indicates that IRTC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.58, IRTC belongs to the top of the industry, outperforming 83.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.71
Quick Ratio 5.58
IRTC Yearly Current Assets VS Current LiabilitesIRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

IRTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.57%, which is quite impressive.
IRTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.55%.
IRTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.49% yearly.
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%

3.2 Future

The Earnings Per Share is expected to grow by 23.39% on average over the next years. This is a very strong growth
IRTC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.85% yearly.
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.39%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.85%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRTC Yearly Revenue VS EstimatesIRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
IRTC Yearly EPS VS EstimatesIRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRTC Price Earnings VS Forward Price EarningsIRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRTC Per share dataIRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as IRTC's earnings are expected to grow with 29.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.04%
EPS Next 3Y29.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRHYTHM TECHNOLOGIES INC

NASDAQ:IRTC (6/18/2025, 8:00:02 PM)

After market: 145.53 0 (0%)

145.53

+0.58 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners112.97%
Inst Owner Change3.7%
Ins Owners1.04%
Ins Owner Change1.94%
Market Cap4.65B
Analysts86.32
Price Target142.8 (-1.88%)
Short Float %7.76%
Short Ratio4.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.27%
Min EPS beat(2)4.68%
Max EPS beat(2)103.85%
EPS beat(4)3
Avg EPS beat(4)6.42%
Min EPS beat(4)-115.67%
Max EPS beat(4)103.85%
EPS beat(8)4
Avg EPS beat(8)-15.15%
EPS beat(12)6
Avg EPS beat(12)-8.91%
EPS beat(16)10
Avg EPS beat(16)-0.35%
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)1.42%
Max Revenue beat(2)2%
Revenue beat(4)2
Avg Revenue beat(4)0.32%
Min Revenue beat(4)-1.42%
Max Revenue beat(4)2%
Revenue beat(8)4
Avg Revenue beat(8)0.32%
Revenue beat(12)6
Avg Revenue beat(12)0.04%
Revenue beat(16)10
Avg Revenue beat(16)1.07%
PT rev (1m)3.63%
PT rev (3m)6.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.99%
EPS NY rev (1m)0%
EPS NY rev (3m)1.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.51
P/FCF N/A
P/OCF 97.77
P/B 53.62
P/tB 54.16
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)1.49
OCFY1.02%
SpS19.37
BVpS2.71
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.62%
ROE -113.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.39%
FCFM N/A
ROA(3y)-22.19%
ROA(5y)-19.41%
ROE(3y)-77.27%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.34%
GM growth 5Y-1.83%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 7.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 233.65%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.71
Quick Ratio 5.58
Altman-Z 3.24
F-Score6
WACC8.51%
ROIC/WACCN/A
Cap/Depr(3y)235.33%
Cap/Depr(5y)237.52%
Cap/Sales(3y)7.91%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.76%
EPS Next Y42.17%
EPS Next 2Y36.04%
EPS Next 3Y29.69%
EPS Next 5Y23.39%
Revenue 1Y (TTM)20.55%
Revenue growth 3Y22.39%
Revenue growth 5Y22.49%
Sales Q2Q%20.27%
Revenue Next Year18.86%
Revenue Next 2Y17.83%
Revenue Next 3Y17.46%
Revenue Next 5Y17.85%
EBIT growth 1Y39.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.59%
EBIT Next 3Y48.61%
EBIT Next 5Y33.49%
FCF growth 1Y97.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.62%
OCF growth 3YN/A
OCF growth 5YN/A